Results 351 to 360 of about 349,757 (388)

Antibody-Drug Conjugate Targets

Current Cancer Drug Targets, 2009
The requirements for a cell surface molecule to be suitable as an antibody-drug conjugate target are stringent. The notion that antibodies-directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The history of antibody-drug conjugates has been marked by hurdles identified and overcome. Early conjugates used
openaire   +2 more sources

Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy

Journal of Cellular Physiology, 2019
Cytotoxic small‐molecule drugs have a major influence on the fate of antibody–drug conjugates (ADCs). An ideal cytotoxic agent should be highly potent, remain stable while linked to ADCs, kill the targeted tumor cell upon internalization and release from
S. Yaghoubi, M. Karimi, M. Lotfinia, Tohid Gharibi, Motahareh Mahi-birjand, Esmaeil Kavi, Fahimeh Hosseini, Koushan Sineh Sepehr, Mehrdad Khatami, N. Bagheri, Meghdad Abdollahpour‐Alitappeh   +10 more
semanticscholar   +1 more source

Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys

Xenobiotica; the fate of foreign compounds in biological systems, 2019
Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) conjugated to a topoisomerase I inhibitor (DXd) at a drug-to-antibody ratio (DAR) of 7-8 ...
Y. Nagai, Masataka Oitate, H. Shiozawa, O. Ando   +3 more
semanticscholar   +1 more source

Antibody–Drug Conjugates for Immunology

Journal of Medicinal Chemistry, 2022
The application of antibody-drug conjugates (ADCs) to fields outside of oncology is increasing but is still relatively uncommon. A recent publication describes the conjugation of glucocorticoid receptor modulators to antibodies as a means of improving the separation between desired anti-inflammatory activity and unwanted systemic side effects.
openaire   +2 more sources

A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.

, 2020
1039Background: PF-06804103 is an anti-HER2 immunoglobulin G1 antibody-drug conjugate (ADC), comprising an anti-HER2 monoclonal antibody conjugated with a cleavable linker to the cytotoxic agent Au...
F. Meric-Bernstam, E. Calvo, V. Moreno, H. Chung, Yeon-Hee Park, Y. Bang, L. Rosen, M. Mita, I. Garrido-Laguna, A. Leung, H. Dube, W. Zhong, Xiaoying Chen, Rula Dawaher, G. Curigliano   +14 more
semanticscholar   +1 more source

Antibody–drug conjugates for cancer

The Lancet, 2019
Antibody-drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC is designed to selectively deliver the ultratoxic payload directly to the target cancer cells.
Cindy H, Chau, Patricia S, Steeg, William D, Figg   +2 more
openaire   +2 more sources

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

The Prostate, 2019
Prostate‐specific membrane antigen (PSMA) is a well‐characterized target that is overexpressed selectively on prostate cancer cells. PSMA antibody‐drug conjugate (ADC) is a fully human IgG1 monoclonal antibody conjugated to the microtubule disrupting ...
D. Petrylak, P. Kantoff, N. Vogelzang, A. Mega, M. Fleming, J. Stephenson, R. Frank, N. Shore, R. Dreicer, E. McClay, W. Berry, Manish Agarwal, V. DiPippo, Y. Rotshteyn, N. Stambler, W. Olson, S. Morris, R. Israel   +17 more
semanticscholar   +1 more source

First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.

, 2020
3551Background: ALT-P7 is an antibody-drug conjugate, in which two molecules of monomethyl auristatin E (MMAE) are site-specifically conjugated to a cysteine-containing peptide motif of trastuzumab...
Yeon-Hee Park, H. Ahn, Ji-yeon Kim, J. Ahn, Y. Im, Seol-Hee Kim, Sunbae Lee, Hye-Shin Chung, Soon-Jae Park   +8 more
semanticscholar   +1 more source

Affinity-bound antibody–drug conjugates

Nature Biomedical Engineering, 2019
Computationally designed antibody–drug conjugates easily self-assemble via affinity ligands that non-covalently link a therapeutic drug to conserved sites on native IgG antibodies.
Christine S. Nervig, Shawn C. Owen
openaire   +2 more sources

Antibody–Drug Conjugates in Tumor Therapy

Pharmaceutical Patent Analyst, 2012
Antibody-drug conjugates (ADCs) for tumor therapy contain a cytotoxic drug conjugated to a monoclonal antibody (mAb) across a linker. A homing device, the mAb enables the recognition of tumor cells by binding to tumor-specific antigens. The linker is usually cleaved inside the tumor cell or close to the cell surface according to a well-designed ...
Sammet, Benedikt, Steinkühler, Christian, Sewald, Norbert   +2 more
openaire   +3 more sources